|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | November 3, 1999 | ||||||||
| Last Updated Date | August 24, 2009 | ||||||||
| Start Date ICMJE | November 1994 | ||||||||
| Estimated Primary Completion Date | September 1997 (final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE | |||||||||
| Original Primary Outcome Measures ICMJE | |||||||||
| Change History | Complete list of historical versions of study NCT00001471 on ClinicalTrials.gov Archive Site | ||||||||
| Current Secondary Outcome Measures ICMJE | |||||||||
| Original Secondary Outcome Measures ICMJE | |||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | Tissue Biopsy and Imaging Studies in HIV-Infected Patients | ||||||||
| Official Title ICMJE | Virologic and Immunologic Evaluation of Lymph Node, Tonsillar, and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid | ||||||||
| Brief Summary | This study will examine tissue from the tonsils, lymph nodes and large bowel of HIV-infected patients to investigate changes in viral load and certain white blood cells during treatment. Normal volunteers and HIV-infected patients 18 years of age or older may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood and urine tests and possibly an electrocardiogram (EKG). Blood tests may include HLA typing, a genetic test of immune system markers. Participants may undergo the following procedures:
|
||||||||
| Detailed Description | Examining tissues outside the bloodstream in HIV-infected patients and, for comparison, HIV uninfected volunteers, can provide insights into the pathogenesis of HIV infection. This protocol will provide a mechanism for sampling tissue sites. A total of 430 HIV-infected patients and 105 HIV uninfected volunteers will be enrolled in these studies. To assess changes in viral load and immunological parameters at sites outside the bloodstream during therapy of HIV-infected patients, sequential tonsillar, lymph node, or intestinal biopsies, or bronchoscopy with bronchoalveolar lavage will be undertaken during the course of therapy. In a small number of patients, sequential or simultaneous lymph node biopsies will be performed. In addition, uninfected healthy volunteers will be enrolled to have a tonsillar or intestinal biopsy or bronchoscopy with bronchoalveolar lavage; this will allow comparison of immunologic parameters in HIV-infected and uninfected tonsillar or intestinal tissues, or bronchoalveolar lavage fluid. |
||||||||
| Study Phase | |||||||||
| Study Type ICMJE | Observational | ||||||||
| Study Design ICMJE | |||||||||
| Condition ICMJE | HIV Infection | ||||||||
| Intervention ICMJE | |||||||||
| Study Arms / Comparison Groups | |||||||||
| Publications * |
|
||||||||
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||
| Enrollment ICMJE | 535 | ||||||||
| Completion Date | |||||||||
| Estimated Primary Completion Date | September 1997 (final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE |
Greater than or equal to 18 years old. Ability to sign informed consent. For women of child-bearing potential, negative result on a serum or urine pregnancy test within 1 week prior to the procedure. Willingness to allow storage of blood or biopsy samples for possible future use to study HIV/AIDS, related diseases or the immune system; willingness to permit HLA testing. FOR PATIENTS UNDERGOING BIOPSIES: No medical contraindication to tonsillar, lymph node, or intestinal biopsy. For tonsillar biopsy, presence of visible tonsillar tissue; for lymph node biopsy, palpable lymph nodes. No aspirin or piroxicam (Feldene) for 10 days prior to the procedure; other non steroidal anti-inflammatory drugs (e.g. ibuprofen) must be discontinued the day prior to the procedure. Acetaminophen [Tylenol] is permitted at any time. FOR PATIENTS UNDERGOING BRONCHOALVEOLAR LAVAGE: Hematocrit greater than 27 percent, platelets greater than 50,000/ml. Baseline pulse-oximetry recording of 94 percent or greater unless clinical indication for bronchoscopy. No medical contraindication to bronchoscopy. FOR HIV POSITIVE VOLUNTEERS: (In addition to the above) HIV infection must be confirmed by ELISA and western blot. For patients with acute HIV infection and negative HIV serology, plasma HIV viral load greater than 10,000 copies/ml. FOR HIV-NEGATIVE VOLUNTEERS: (In addition to the above) No underlying significant medical problem, especially an immunodeficiency or autoimmune disease, or an underlying problem requiring immunosuppressive therapy. Absence of HIV infection as confirmed by negative ELISA and, if indicated, western blot. EXCLUSION CRITERIA: FOR ALL VOLUNTEERS UNDERGOING BIOPSIES: Platelet count less than 75,000 platelets/mm(3). PT or PTT prolonged by greater than 2 seconds. Known underlying bleeding disorder. Pregnancy. FOR HIV-POSITIVE VOLUNTEERS FOR LYMPH NODE BIOPSIES: Use of narcotics (other than as prescribed by a physician) or cocaine less than 1 week prior to the date of biopsy. FOR ALL VOLUNTEERS FOR INTESTINAL BIOPSIES: Use of narcotics (other than as prescribed by a physician) or cocaine less than 1 week prior to the date of biopsy. Significant heart valve abnormalities. Presence of pacemaker, artificial joint or vascular surgery graft. FOR ALL VOLUNTEERS FOR BRONCHOSCOPY: Use of narcotics (other than as prescribed by a physician) or cocaine less than 1 week prior to the date of biopsy. Pregnancy. Any medical condition for which the investigators believe bronchoscopy may be contraindicated. Allergy to lidocaine. History of asthma requiring therapy. |
||||||||
| Gender | Both | ||||||||
| Ages | 18 Years and older | ||||||||
| Accepts Healthy Volunteers | Yes | ||||||||
| Contacts ICMJE |
|
||||||||
| Location Countries ICMJE | United States | ||||||||
| Administrative Information | |||||||||
| NCT ID ICMJE | NCT00001471 | ||||||||
| Responsible Party | |||||||||
| Study ID Numbers ICMJE | 950027, 95-I-0027 | ||||||||
| Study Sponsor ICMJE | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||
| Collaborators ICMJE | |||||||||
| Investigators ICMJE | |||||||||
| Information Provided By | National Institutes of Health Clinical Center (CC) | ||||||||
| Verification Date | July 2009 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||